Hyzaar

Hyzaar is used for treating high blood pressure. It may be used to decrease the risk of stroke in certain patients with high blood pressure.

Product dosage: 50mg
Package (num)	Per pill	Price	Buy
30	$1.73	$52.00 (0%)	🛒 Add to cart
60	$1.50	$104.00 $90.00 (13%)	🛒 Add to cart
90	$1.42	$156.00 $128.00 (18%)	🛒 Add to cart
120	$1.38	$208.00 $165.00 (21%)	🛒 Add to cart
180	$1.34	$312.00 $241.00 (23%)	🛒 Add to cart
270	$1.31	$468.00 $355.00 (24%)	🛒 Add to cart
360	$1.31 Best per pill	$624.00 $470.00 (25%)	🛒 Add to cart

Hyzaar represents a significant advancement in the management of hypertension, combining two established antihypertensive agents into a single, convenient tablet. This fixed-dose combination therapy integrates the angiotensin II receptor blocker (ARB) losartan potassium with the thiazide diuretic hydrochlorothiazide (HCTZ), offering a synergistic approach to blood pressure reduction. By targeting multiple physiological pathways involved in blood pressure regulation, Hyzaar provides clinicians with a powerful tool for patients requiring more than monotherapy. Its well-documented efficacy and generally favorable tolerability profile have made it a cornerstone in modern antihypertensive treatment strategies, particularly for patients whose blood pressure remains uncontrolled on single-agent therapy.

Features

• Contains 50 mg losartan potassium and 12.5 mg hydrochlorothiazide per tablet
• Film-coated, oval-shaped tablets imprinted with “HYZAAR” on one side
• Available in bottles of 30, 90, and 500 tablets
• Requires prescription-only dispensing
• Manufactured under strict pharmaceutical quality control standards
• Stable at room temperature with protection from moisture and light

Benefits

• Provides superior blood pressure reduction compared to either component alone through complementary mechanisms of action
• Reduces the pill burden for patients requiring multiple antihypertensive agents, potentially improving adherence
• Offers convenient once-daily dosing that supports consistent therapeutic coverage
• Demonstrates proven cardiovascular risk reduction in appropriate patient populations
• May preserve potassium balance better than thiazide diuretic monotherapy due to losartan’s effects
• Shows established efficacy across diverse demographic groups including elderly patients

Common use

Hyzaar is primarily indicated for the treatment of hypertension in patients for whom combination therapy is appropriate. This typically includes individuals whose blood pressure is not adequately controlled on losartan or hydrochlorothiazide monotherapy, or those who are initiated on combination therapy based on clinical assessment of their cardiovascular risk profile. The medication may also be used as replacement therapy in patients already stabilized on the individual components taken separately. Clinical decision-making should consider the patient’s baseline blood pressure, target goals according to current guidelines, presence of compelling indications, and individual response to previous antihypertensive regimens.

Dosage and direction

The usual recommended starting dose of Hyzaar is one tablet (50 mg losartan/12.5 mg HCTZ) taken orally once daily. dosage may be increased to two tablets once daily after 2-4 weeks if blood pressure remains uncontrolled. The maximum recommended daily dose is 100 mg losartan/25 mg HCTZ. Administration may occur with or without food, though consistency in timing relative to meals is advised. Tablet should be swallowed whole with a glass of water. dosage adjustment may be necessary for patients with renal impairment, hepatic insufficiency, or volume depletion. Elderly patients may initiate therapy at the same dosage as younger adults unless contraindications exist.

Precautions

Patients should be monitored for electrolyte imbalances (particularly hypokalemia, hyponatremia, and hypomagnesemia) especially during initial titration and during concomitant use of other medications affecting electrolyte balance. Regular assessment of renal function is recommended, as deterioration may occur in susceptible individuals. Caution is advised in patients with impaired hepatic function or history of hepatic disease due to possible reduced losartan metabolism. Photosensitivity reactions may occur due to hydrochlorothiazide component; appropriate sun protection measures are recommended. Orthostatic hypotension may develop, particularly in volume-depleted patients or those receiving concomitant vasodilators. Regular blood pressure monitoring is essential to assess therapeutic response and guide dosage adjustments.

Contraindications

Hyzaar is contraindicated in patients with known hypersensitivity to any component of the formulation or other sulfonamide-derived drugs. Anuria and significant renal impairment (creatinine clearance <30 mL/min) represent absolute contraindications due to reduced drug clearance. The medication must not be used during pregnancy, particularly during the second and third trimesters, due to potential fetal harm. Concomitant use with aliskiren in patients with diabetes is contraindicated. Severe hepatic impairment, biliary cirrhosis, or cholestasis preclude use due to altered pharmacokinetics. Pre-existing significant hypokalemia or hypercalcemia that cannot be corrected also contraindicates therapy.

Possible side effects

Common adverse reactions (≥1% incidence) include dizziness, upper respiratory infection, cough, hyperkalemia, hypokalemia, hypotension, orthostatic hypotension, diarrhea, nausea, muscle cramps, and rash. Less frequent but potentially serious side effects may include renal impairment, hepatic dysfunction, pancreatitis, electrolyte disturbances, photosensitivity reactions, and hematological abnormalities. Rare cases of angioedema involving the face, lips, throat, and/or tongue have been reported. Patients should be instructed to report any signs of allergic reactions, unusual bleeding or bruising, persistent dry cough, muscle weakness, or significant changes in urinary output. Most side effects are dose-dependent and may be managed through dosage adjustment or discontinuation.

Drug interaction

Significant interactions may occur with other medications affecting the renin-angiotensin-aldosterone system, including ACE inhibitors and direct renin inhibitors, potentially increasing risks of hyperkalemia, hypotension, and renal impairment. Nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce the antihypertensive effect and increase risk of renal dysfunction. Concomitant use with potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium may lead to hyperkalemia. Lithium levels may increase due to reduced renal clearance when administered with thiazide diuretics. Enhanced hypotensive effects may occur with alcohol, barbiturates, or narcotics. Cholestyramine and colestipol may reduce absorption of hydrochlorothiazide. Insulin requirements may be altered in diabetic patients.

Missed dose

If a dose is missed, it should be taken as soon as remembered on the same day. If remembered near the time of the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed administration. Consistent daily dosing is important for maintaining stable blood pressure control, so patients should be counseled on establishing a routine for medication administration. Use of pill organizers or reminder systems may help prevent missed doses. If multiple doses are missed, blood pressure should be monitored and healthcare provider consulted regarding appropriate management.

Overdose

Symptoms of overdose may include hypotension, tachycardia, bradycardia, dizziness, decreased urinary output, electrolyte disturbances, and renal impairment. Management should focus on supportive care with correction of fluid and electrolyte imbalances. Gastric lavage may be considered if ingestion occurred recently. Activated charcoal may be administered if appropriate. Hypotension should be managed with intravenous normal saline; vasopressors may be required in severe cases. Hemodialysis is not effective for removing losartan but may remove hydrochlorothiazide. Close monitoring of vital signs, electrolyte status, and renal function is essential. Specific treatment should be directed by poison control center or medical toxicologist.

Storage

Store at controlled room temperature (20-25°C or 68-77°F) with excursions permitted between 15-30°C (59-86°F). Keep container tightly closed and protect from moisture and light. Keep out of reach of children and pets. Do not use after expiration date printed on packaging. Properly discard any unused medication that is no longer needed or has expired through medication take-back programs or according to FDA guidelines. Do not flush medications down the toilet or pour into drain unless specifically instructed to do so.

Disclaimer

This information is provided for educational purposes only and does not constitute medical advice. Individual patient responses to medication may vary. Healthcare professionals should exercise their own professional judgment when considering the use of this product. Patients should not make changes to their medication regimen without consulting their healthcare provider. Full prescribing information including boxed warnings should be reviewed before initiating therapy. The content here reflects information available at the time of writing and may not include the most recent updates to safety information or labeling changes.

Reviews

Clinical studies have demonstrated that Hyzaar produces significantly greater reductions in systolic and diastolic blood pressure compared to either component alone. In randomized controlled trials, approximately 70-80% of patients achieved blood pressure control with Hyzaar therapy. Long-term extension studies have shown maintained efficacy over treatment periods exceeding one year. Real-world evidence supports the effectiveness of this combination in diverse patient populations, though individual responses may vary based on genetic factors, comorbidities, and concomitant medications. Patient satisfaction surveys indicate appreciation for the convenience of combination therapy, though some report concerns about cost compared to generic monotherapies. Healthcare providers generally regard Hyzaar as a valuable option for patients requiring stepped-care approach to hypertension management.